Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

The HCN4 Channel Mutation D553N Associated With Bradycardia Has a C-linker Mediated Gating Defect

Netter M.F.a · Zuzarte M.b · Schlichthörl G.b · Klöcker N.c · Decher N.a

Author affiliations

a Institute of Physiology and Pathophysiology, Vegetative Physiology Group, Philipps University of Marburg; b Institute of Physiology and Pathophysiology, Cardiovascular Cellphysiology Group, Philipps University of Marburg; c Institute of Neuro- and Sensory Physiology, Medical Faculty, University of Düsseldorf

Corresponding Author

Niels Decher

Institut für Physiologie, Vegetative Physiologie,

Universität Marburg, Deutschhausstraße 1-2, 35037 Marburg (Germany)

Tel. +49 6421 28 62148, Fax +49 6421 28 66659, E-Mail decher@staff.uni-marburg.de

Related Articles for ""

Cell Physiol Biochem 2012;30:1227-1240

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Background/Aims: The D553N mutation located in the C-linker of the cardiac pacemaker channel HCN4 is thought to cause sino-atrial dysfunction via a pronounced dominant-negative trafficking defect. Since HCN4 mutations usually have a minor defect in channel gating, it was our aim to further characterize the disease causing mechanism of D553N. Methods: Fluorescence microscopy, FACS, TEVC and patch-clamp recordings were performed to characterize D553N. Results: Surprisingly, we found that D553N channels reach the plasma membrane and have no apparent trafficking defect. Co-expression of D553N with HCN4 also revealed no dominant-negative effect on wild-type channels. Consistent with the normal cell surface expression of D553N, it was possible to extensively characterize D553N mutants in Xenopus oocytes and mammalian cells. D553N channels generate currents with reduced amplitude, while the kinetics of activation and deactivation are not altered. While the regulation of D553N by tyrosine kinases is normal, we observed a change in the cAMP regulation which however cannot account for the strong loss-of-function of the mutant. Conclusion: The pronounced current reduction and the regular surface expression indicate a major gating defect of the C-linker gate. We hypothesize that the D553N mutation stabilizes a previously reported salt bridge important for the gating of the channel.

© 2012 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: August 24, 2012
Published online: October 15, 2012
Issue release date: November 2012

Number of Print Pages: 14
Number of Figures: 2
Number of Tables: 0

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: http://www.karger.com/CPB

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.